https://www.thebodypro.com/category/atripla-pro

Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla)

The Latest

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy Img
Conference Coverage

Racial Differences Seen in Comparison of Stribild and Atripla as First-Line Therapy

A new study finds that black people are less likely to keep their viral load down on Atripla -- and that more trouble with side effects may be the reason.

Promo Image
Neurocognitive

Sustiva, Atripla Tied to Neurologic Toxicity

A team of researchers from Johns Hopkins University School of Medicine reported that the way the body metabolizes the HIV medication efavirenz may contribute to cognitive (brain function-related) impairment. Efavirenz is sold under the brand name Sus...

Antiretroviral Rounds: Resistance on Two Fronts Img
News

Antiretroviral Rounds: Resistance on Two Fronts

Got this challenging curbside consult from a colleague, and it has a interesting wrinkle:

I have a longstanding patient with HIV who had many failed regimens in the 1990's with resultant following mutations on a genotype done in 2003:

NRTI (M1...

Promo Image

20% People Switch Atripla Due to Efavirenz Side Effects: Late Switches Are Common

The experience from use of fixed-dose combination, efavirenz-based treatment (Atripla) as first-line therapy in the UK was published ahead of print in the journal AIDS.

This analysis included 472 patients from the Chelsea and Westminster Hospital in...

Promo Image

Atripla

Brand name: Atripla

Generic name: efavirenz/emtricitabine/tenofovir, or EFV/FTC/TDF

Class: NNRTI and NRTI -- single-tablet regimen (STR)

Manufacturer: Bristol-Myers Squibb, www.bms.com, (800) 321-1335, and Gilead Sciences, www.gilead.com, (800) GI...

Promo Image
Conference Coverage

Gilead's Quad Single Tablet Regimen for HIV Non-Inferior to Atripla in Pivotal Phase 3 Study

Seattle, Wash. -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced full Phase 3 clinical trial results from pivotal Study 102 demonstrating that the Quad, a once-daily single tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir...

Promo Image
News

Complera and Atripla News

Last summer, 48-week data won FDA approval for Complera (see the November/December 2011 "Briefly" for the complicated details). At IDSA, 96-week data were presented from the ECHO and THRIVE studies that pitted the new Complera against Atripla. Comple...

Promo Image
News

Switching From Atripla to Complera

Now that the best-selling Atripla has a real competitor, an important question becomes, can people switch from Atripla to the new Complera?

While switching to a new and improved drug or regimen is common, there was a concern about switching here bec...

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings Img
News

ICAAC HIV Poster Roundup #1: Clinically Relevant Findings

Here's a quick sampling of some of the more noteworthy HIV-related posters presented at a major research conference last week. Topics covered include a surprisingly high frequency of people quitting Atripla due to side effects; the decline of multidr...

Promo Image
News

Atripla's Co-Pay Program Now Saves More Money

The co-pay program for Atripla now eliminates the requirement that people first pay $50 out-of-pocket before financial assistance begins. The same is true for the drugs that make up Atripla (Sustiva and Truvada), as well as the medications that make ...